Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising ...

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at markets.businessinsider.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

Clearmind Medicine and Neurothera Labs have published a U.S. patent application for a novel MDMA and N-acylethanolamines combination to treat PTSD, leveraging FDA's new dedicated regulatory framework for psychedelic drug development including MDMA.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

FDA guidance embedding MDMA in psychedelic drug regulation clears a pathway for you to develop MDMA-linked treatments with clearer clinical protocols and patent advantages.

◆ Coverage

1 source · 24 Aug 2026

◆ Related on Wire

◆ Topics

Biotechmdmaptsd-treatmentpsychedelic-drugsfda-guidancepatent-ipneurotherapeutics